Evidence map›Paper›PMID 36116584›Full record

Trial reportJournal of the American Academy of Dermatology2022

Anakinra for refractory pustular psoriasis: A phase II, open-label, dose-escalation trial.

Haley B Naik, Dominique C Pichard, Daniella M Schwartz, Michelle O'Brien, Matthew Masciocchi, Julie Thompson, H Nida Sen, Seth M Steinberg, Sandra A Mitchell, Adriana A de Jesus and 7 more

Open access · greenAbstract readClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of the American Academy of Dermatology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
3.0field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Signaling pathways and targeted therapies for psoriasis.Signal transduction and targeted therapy · 2023
    Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 8 institutions in 1 country.

Haley B NaikDepartment of Dermatology, University of California, San Francisco, California. Electronic address: Haley.Naik@ucsf.edu.
Dominique C PichardDermatology Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, Maryland.
Daniella M SchwartzLaboratory of Allergic Diseases, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland.
Michelle O'BrienDermatology Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, Maryland.
Matthew MasciocchiRadiation Oncology Branch, National Cancer Institute, Bethesda, Maryland.
Julie ThompsonDermatology Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, Maryland.
H Nida SenClinical and Translational Immunology Unit, Laboratory of Immunology, National Eye Institute, Bethesda, Maryland.
Seth M SteinbergBiostatistics and Data Management Section, Office of the Clinical Director, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland.
Sandra A MitchellDivision of Cancer Control and Population Sciences, Outcomes Research Branch, National Cancer Institute, Rockville, Maryland.
Adriana A de JesusTranslational Autoinflammatory Diseases Section (TADS), LCIM, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland.
Timothy H McCalmontDepartment of Dermatology, University of California, San Francisco, California; Department of Pathology, University of California, San Francisco, California.
Amit DeySection of Inflammation and Cardiovascular Diseases, National Institute of Heart, Lung and Blood Diseases, Bethesda, Maryland.
Rachel K RosensteinDermatology Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, Maryland.
Zuoming DengBiodata Mining and Discovery Section, Office of Science and Technology, National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, Maryland.
Raphaela Goldbach-ManskyTranslational Autoinflammatory Diseases Section (TADS), LCIM, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland.
Nehal N MehtaSection of Inflammation and Cardiovascular Diseases, National Institute of Heart, Lung and Blood Diseases, Bethesda, Maryland.
Edward W CowenDermatology Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, Maryland.
National Institute of Arthritis and Musculoskeletal and Skin Diseases · USNational Institute of Allergy and Infectious Diseases · USNational Cancer Institute · USNational Heart Lung and Blood Institute · USUniversity of California, San Francisco · USNational Eye Institute · USOffice of Science · USOffice of the Director · US

Funding

Anakinra for neutrophilic pustular skin diseaseZIABC011550 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI COWEN, EDWARD · 2014 to 2021
$1.7M
BIOSTATISTICS AND DATA MANAGEMENT SECTIONZ01SC007202 · SC · DIVISION OF CLINICAL SCIENCES - NCI · PI STEINBERG, SETH M · 1996 to 2008
$1.5M
Microbial Shifts and Immune Dysregulation in Hidradenitis Suppurativa PathogenesisK23AR074531 · NIAMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI NAIK, HALEY · 2019 to 2023
$887k
Anakinra for neutrophilic pustular skin diseaseZIAAR041228 · NIAMS · NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES · PI COWEN, EDWARD · 2022 to 2022
$14k
Intramural NIH HHS Z01 SC007202Intramural NIH HHS ZIA AR041228Intramural NIH HHS ZIA BC011550NIAMS NIH HHS K23 AR074531
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Dermatologic AgentsPsoriasisSkin Diseases, VesiculobullousHumansInterleukin 1 Receptor Antagonist ProteinDermatologic AgentsInterleukin 1 Receptor Antagonist Protein

Identifiers

PMID36116584
PMCPMC10673680
OpenAlexW4296201771

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.